heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.
Company profile
Ticker
BEAT, BEATW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
474881450
BEAT stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
Departure of Directors or Certain Officers
5 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
HeartBeam Appoints Dr. Michael R. Jaff to the Board of Directors
26 Jul 23
S-8
Registration of securities for employees
13 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
11 Jul 23
8-K
HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors
8 Jun 23
DEF 14A
Definitive proxy
26 May 23
Transcripts
BEAT
Earnings call transcript
2023 Q4
20 Mar 24
BEAT
Earnings call transcript
2023 Q3
14 Nov 23
BEAT
Earnings call transcript
2023 Q2
10 Aug 23
BEAT
Earnings call transcript
2023 Q1
11 May 23
BEAT
Earnings call transcript
2022 Q4
16 Mar 23
BEAT
Earnings call transcript
2022 Q3
10 Nov 22
BEAT
Earnings call transcript
2022 Q2
12 Aug 22
Latest ownership filings
SC 13D
STROME MARK E
25 Oct 23
4
Urioste George de
3 Oct 23
4
Urioste George de
29 Sep 23
4
Urioste George de
27 Sep 23
4
Urioste George de
22 Sep 23
4
Urioste George de
19 Sep 23
4
Urioste George de
15 Sep 23
SC 13D
PUBLIC VENTURES, LLC
28 Aug 23
4
Kenneth Harry Persen
4 Aug 23
4
Branislav Vajdic
4 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.21 mm | 19.21 mm | 19.21 mm | 19.21 mm | 19.21 mm | 19.21 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.25 mm | 1.25 mm | 699.33 k | 1.02 mm |
Cash used (since last report) | n/a | n/a | 8.58 mm | 8.57 mm | 4.81 mm | 6.99 mm |
Cash remaining | n/a | n/a | 10.63 mm | 10.63 mm | 14.39 mm | 12.21 mm |
Runway (months of cash) | n/a | n/a | 8.5 | 8.5 | 20.6 | 12.0 |
Institutional ownership, Q2 2023
8.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 17 |
Closed positions | 5 |
Increased positions | 8 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 3.89 bn |
Total shares | 2.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 500.00 k | $200.00 mm |
Geode Capital Management | 208.52 k | $502.52 mm |
Smith, Salley & Associates | 200.00 k | $482.00 mm |
UBS UBS Group AG - Registered Shares | 161.32 k | $388.78 mm |
Vanguard | 155.64 k | $375.09 mm |
Beacon Pointe Advisors | 133.33 k | $321.34 mm |
SF Stifel Financial | 100.00 k | $241.00 mm |
Advisory Research | 100.00 k | $241.00 mm |
Kestra Private Wealth Services | 67.37 k | $162.35 mm |
Baker Avenue Asset Management | 66.67 k | $160.67 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.06 | 5,500 | 11.33 k | 36,129 |
28 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.04 | 8,000 | 16.32 k | 41,629 |
27 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.11 | 1,834 | 3.87 k | 49,629 |
26 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.09 | 5,000 | 10.45 k | 51,463 |
22 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.21 | 2,393 | 5.29 k | 56,463 |
21 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.41 | 100 | 241.00 | 58,856 |
20 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.46 | 883 | 2.17 k | 58,956 |
18 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.46 | 5,000 | 12.30 k | 59,839 |
15 Sep 23 | Urioste George De | Common Stock | Sell | Dispose S | No | No | 2.43 | 4,269 | 10.37 k | 64,839 |
News
HeartBeam Presents Results On AI Capabilities For Detecting Arrhythmias
9 Apr 24
Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target
25 Mar 24
Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
22 Mar 24
Recap: HeartBeam Q4 Earnings
20 Mar 24
HeartBeam Q4 2023 GAAP EPS $(0.13), Inline
20 Mar 24
Press releases
HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
9 Apr 24
HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results
20 Mar 24
First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo™ System for Synthesizing a 12-Lead ECG
14 Mar 24
HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology
7 Mar 24
HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time
5 Mar 24